TRCT
BCYC

Tower Research Capital (TRC)’s Bicycle Therapeutics BCYC Stock Holding History

Tower Research Capital (TRC)’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Buy
3,669
+1,703
+87% +$7.81K ﹤0.01% 3759
2026
Q1 		$9.12K Buy
1,966
+298
+18% +$1.7K ﹤0.01% 3940
2025
Q4 		$11.8K Buy
1,668
+3
+0.2% +$22 ﹤0.01% 3548
2025
Q3 		$12.9K Sell
1,665
-2,494
-60% -$18.8K ﹤0.01% 3741
2025
Q2 		$28.9K Buy
4,159
+3,078
+285% +$24.5K ﹤0.01% 3433
2025
Q1 		$9.18K Buy
1,081
+156
+17% +$1.84K ﹤0.01% 3814
2024
Q4 		$12.9K Buy
925
+296
+47% +$6.34K ﹤0.01% 3570
2024
Q3 		$14.2K Sell
629
-1,720
-73% -$39.7K ﹤0.01% 3471
2024
Q2 		$47.5K Buy
2,349
+1,938
+472% +$43.8K ﹤0.01% 3140
2024
Q1 		$10.2K Sell
411
-1,917
-82% -$40.7K ﹤0.01% 3724
2023
Q4 		$42.1K Sell
2,328
-7,539
-76% -$125K ﹤0.01% 3241
2023
Q3 		$198K Buy
9,867
+7,447
+308% +$170K 0.01% 1440
2023
Q2 		$61.8K Buy
2,420
+1,157
+92% +$26.9K ﹤0.01% 2415
2023
Q1 		$27K Buy
1,263
+99
+9% +$2.48K ﹤0.01% 3093
2022
Q4 		$35K Sell
1,164
-1,099
-49% -$29.5K ﹤0.01% 2602
2022
Q3 		$53K Buy
2,263
+1,184
+110% +$28.2K ﹤0.01% 3109
2022
Q2 		$18K Buy
1,079
+683
+172% +$14.4K ﹤0.01% 3886
2022
Q1 		$17K Sell
396
-3,331
-89% -$156K ﹤0.01% 3674
2021
Q4 		$227K Buy
+3,727
New +$206K ﹤0.01% 1658
2019
Q4 		– Sell
-92
Closed -$1K – 3545
2019
Q3 		$1K Buy
92
+91
+9,100% +$782 ﹤0.01% 3817
2019
Q2 		$0 Buy
+1
New +$12 ﹤0.01% 3667

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Tower Research Capital (TRC)'s BCYC Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Bicycle Therapeutics (BCYC) stake by 87% in Q2 2026, buying an estimated $7.81K and bringing the position to 3,669 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3759.

Tower Research Capital (TRC) first reported a position in BCYC in Q2 2019 and has held it in 21 quarters since. The position peaked at $227K in Q4 2021. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Tower Research Capital (TRC) held 3,669 shares of Bicycle Therapeutics worth $15.6K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,703 Bicycle Therapeutics shares in Q2 2026, an estimated $7.81K.
  • Bicycle Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3759 holding.
  • Tower Research Capital (TRC) first reported a position in Bicycle Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Bicycle Therapeutics position peaked at $227K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.